Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00537628 · ClinicalTrials.gov registry record
Biomarkers in Acute Heart Failure
A clinical trial, sponsored by Brahms.
- Completed
- Registry status
- 1,641
- Enrollment target
NCT00537628: Completed study, sponsored by Brahms.
NCT00537628 is a clinical trial that has completed, run by Brahms. The registered enrollment target is 1,641 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00537628 has completed, sponsored by Brahms.
- COMPLETED
- Registry status
- 1,641 participants
- Enrollment target
Study Summary
Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuretic Peptide (MR-proANP) is non-inferior to BNP for the diagnosis of HF in patients presenting to the ED with shortness of breath.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,641 participants |
| Start Date | 2007-03 |
| Est. Completion | 2008-06 |
What the finished NCT00537628 record still lists
NCT00537628 is an observational study that tracks outcomes without assigning an intervention. Its 1,641 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00537628 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00537628 about?
NCT00537628 is a clinical study titled "Biomarkers in Acute Heart Failure". Primary Objectives 1. Mid Region pro Adrenomedullin (MR-proADM) is superior to BNP for the prognosis of heart failure (HF) patients and adds incremental value in predicting outcomes for patients presenting to the Emergency Department (ED) with shortness of breath. 2. Mid Region pro A-Type Natriuret...
What is the current status of trial NCT00537628?
This trial is currently completed. The enrollment target is 1,641 participants. The study started on 2007-03. Estimated completion is 2008-06.
Who is sponsoring clinical trial NCT00537628?
This trial is sponsored by Brahms, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- NCT07046260 · 1,650 participants
Prospective Study to Assess a Diagnostic Aid for Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia